权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

STUDIES OF AN AFRICAN POPULATION ENDEMIC FOR HTLV

非洲人群 HTLV 流行病的研究

基本信息

批准号：
3183737
负责人：
Martin nmi Haas
金额：
$ 14.88万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
1986
资助国家：
美国
起止时间：
1986-09-30 至 1988-08-31
项目状态：
已结题

项目摘要

Our preliminary sero-epidemiologic survey of ethnic groups in Israel has shown that 37% of healthy Falasha individuals ("Black Jews" of Ethopian decent) have antibodies for HTLV-I and -II.* This is the highest known prevalence of antibody to HTLV in any population and indicates widespread infection with HTLV. HTLV is an exogenous virus and is associated with the development of several human malignancies. Sero-epidemiologic studies will be performed to (i) characterize the clinically relevant biologic activities; (ii) detect the exact mode of horizontal transmission of the virus; (iii) study virus-host interactions including determinations of host-range and localization and overlap of different types of HTLV. The hypothesis will be tested that prevalence of HTLV antibodies is correlated with antibodies to other viruses implicated in human malignancy, specifically CMV, EBV, and HBV. A cross-sectional study will be done to confirm the hypothesis that HTLV antibodies are associated with specific T-cell malignancy, and to probe for new and unrecognized disease associations. Prospective studies will test the mode of HTLV transmission of mother to child and will characterize the immune response of neonatal HTLV infection. Absorption enzyme immunoassay studies suggest that sero-positive Falashas carry a new subtype of HTLV that crossreacts with HTLV types I and II but differs from them. HTLV will be isolated from the lymphocytes of seropositive Falasha individuals, grown in culture, and purified in quantity. An ELISA test will be established and competition immunoassays among HTLV types -I, -II, and -Falasha will be performed. HTLV isolated from Falasha individuals will be molelcularly cloned, restriction maps will be derived, and selected regions of the viral genome will be sequenced and compared with other subtypes of the group. * In addition, 10% of these have antibodies to HTLV-III as well.

我们对以色列少数民族的初步血清流行病学调查研究显示，37%的健康法拉沙人(埃索比亚人的“黑人犹太人”) 有HTLV-I和-II抗体。*这是已知的最高水平 HTLV抗体在任何人群中的流行率，并表明普遍存在感染HTLV。HTLV是一种外源性病毒，与几种人类恶性肿瘤的发展。将进行血清流行病学研究，以(I)确定临床上相关的生物学活动；(Ii)检测病毒的水平传播；(Iii)研究病毒与宿主的相互作用包括寄主范围的确定以及本地化和重叠不同类型的HTLV。这一假设将得到检验，即 HTLV抗体与涉及的其他病毒抗体相关在人类的恶性肿瘤中，特别是巨细胞病毒、EB病毒和乙肝病毒。一个横截面将进行研究以证实HTLV抗体是与特定的T细胞恶性肿瘤相关，并探索新的和未被认可的疾病关联。前瞻性研究将测试这一模式母婴传播HTLV，并将成为免疫的特征新生儿HTLV感染的反应。吸收酶免疫分析研究表明，血清阳性的法拉沙携带一种新的HTLV亚型，与HTLV I型和II型发生交叉反应，但与他们不同。HTLV将从猪的淋巴细胞中分离出来血清阳性的法拉沙个体，在培养中生长，并在数量。将建立一个酶联免疫吸附试验和竞争免疫分析在HTLV类型-I、-II和-Falasha中，将执行Falasha。HTLV隔离来自法拉沙的个体将被分子克隆，限制图将并将对病毒基因组的选定区域进行测序和与本组其他亚型比较。 *此外，其中10%的人也有HTLV-III抗体。